Home › Employers › Aquinnah Pharmaceuticals Inc.
Aquinnah Pharmaceuticals Inc.: H-1B salaries and sponsorship
Aquinnah Pharmaceuticals Inc. filed 4 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $88,000.
Does Aquinnah Pharmaceuticals Inc. sponsor H-1B visas?
Aquinnah Pharmaceuticals Inc. filed 4 labor condition applications in fiscal years 2023–2026, the latest submitted on Jun 13, 2024. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Senior Fellow | 2 | — |
| Senior Research Associate | 2 | $88,000 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2023 | 2 | — |
| FY2025 | 2 | $88,000 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Senior Research Associate | $86,000 Level I | Cambridge, MA | Jun 13, 2024 | Jul 1, 2024 | Certified, then withdrawn |
| Senior Research Associate | $90,000 Level II | Cambridge, MA | Apr 6, 2023 | Sep 29, 2023 | Certified, then withdrawn |
| Senior Fellow | $260,000 part-time · Level III | Cambridge, MA | Nov 17, 2022 | Nov 21, 2022 | Certified |
| Senior Fellow | $260,000 part-time · Level III | Cambridge, MA | Nov 17, 2022 | Nov 21, 2022 | Withdrawn |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).